Adrenocortical insufficiency (AI) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 Adrenal insufficiency (AI) or Addison’s disease is a rare disorder characterized by inadequate cortisol and aldosterone production. The symptoms of classic Addison’s disease, also known as primary adrenal insufficiency, result from the insufficient production of these two hormones, cortisol and aldosterone. Diagnosis measures the adrenal corticosteroid hormones, their regulatory peptide hormones, and stimulation tests. It is classified as primary adrenal insufficiency (PAI) or secondary adrenal insufficiency (SAI). PAI results from intrinsic disease to the adrenal cortex, most commonly due to autoimmune adrenalitis. Due to pituitary disease, SAI is caused by insufficient or deficient corticotropin production. The most common cause of adrenal insufficiency is glucocorticoid-induced adrenal insufficiency (GIAI), a unique form of SAI caused by long-term iatrogenic glucocorticoid use.

In the USA, the prevalence of Adrenal insufficiency (AI) ranges between 55  to 140 cases per million population.

 

The competitive landscape of Adrenocortical insufficiency (AI)  includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Adrenocortical insufficiency (AI)  across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Adrenocortical insufficiency (AI)  Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Adrenocortical insufficiency (AI)  – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Hydrocortisone  Shire    Phase 2/3

2          Infacort®          Diurnal Limited  Phase 3

3          Mifepristone      Corcept Therapeutics    Phase 2

4          MIN-102           Minoryx Therapeutics, S.L.        Phase 2/3

5          MD1003            MedDay Pharmaceuticals SA     Phase 2/3

6          hematopoietic stem cell infusion Talaris Therapeutics Inc.            Phase 1/2

7          VK0214 Viking Therapeutics, Inc.           Phase 1

8          Cholic Acids      Travere Therapeutics, Inc.         Phase 3

9          Alkindi   EffRx Pharmaceuticals SA         Phase 3